Immix Biopharma, Inc.
IMMXImmix Biopharma, Inc. in brief
Immix Biopharma, Inc. is a listed company in the Biotechnology industry, based in Los Angeles, California, USA. Its market value was $675 M on 28 October 2026, which makes it the 11,268th largest listed company in the world and the 2,337th largest in the USA on this site. It employs about 21 people and Ilya M. Rachman is its chief executive. Its shares trade under the symbol IMMX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the application of chimeric antigen receptor cell therapy in light chain (AL) Amyloidosis and other serious diseases. Our lead cell therapy candidate is CAR-T NXC-201, currently being evaluated in our ongoing United States Phase 1b/2 NEXICART-2 (NCT06097832) clinical trial and an ex-U.S. phase 1b/2a NEXICART-1 (NCT04720313) clinical trial. NEXICART-2 is expected to enroll 40 patients, with final readout and Biologics License Application submission planned thereafter.
NXC-201 has been awarded Regenerative Medicine Advanced Therapy Designation by the FDA, Orphan Drug Designation by both the FDA and European Commission in AL Amyloidosis and, most recently, in January 2026, Breakthrough Therapy designation by the FDA for the treatment of relapsed/refractory AL amyloidosis.
From the company's annual report filed with the US SEC: read the report
Immix Biopharma, Inc. timeline
- 2021
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 17 December 2021; shares registered for exchange trading on 13 December 2021.
Events of Immix Biopharma, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #5,083 (Dec 2022) · #4,970 (Jul 2023) · #3,572 (Jan 2024) · #1,238 (Mar 2026) · #2,245 (Aug 2026) · #2,238 (Oct 2026) · #2,339 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 7.2×
- Free cash flow yield
- -3.7%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -31.4%
- Liabilities / assets
- 10.5%
- Profit per employee
- $-1.4 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-30M | $-29M | — |
| Dec 2024 | — | — | $-23M | $-22M | — |
| Dec 2023 | — | — | $-16M | $-15M | — |
| Dec 2022 | — | — | $-8M | $-8M | — |
| Dec 2021 | — | — | $-1M | $-24M | — |
| Dec 2020 | — | — | $-0M | $-1M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-24M | $1M | $-25M | $-0.89 | — |
| Dec 2024 | $-15M | $1M | $-16M | $-0.76 | — |
| Dec 2023 | $-11M | $0M | $-11M | $-0.89 | — |
| Dec 2022 | $-7M | — | — | $-0.59 | — |
| Dec 2021 | $-2M | $0M | $-2M | $-6.64 | — |
| Dec 2020 | $-0M | — | — | $-0.34 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-14M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Sep 30, 20268-KCurrent reportOther events
- Sep 29, 20268-KCurrent reportRegulation FD disclosure · Other events
- Aug 7, 202610-QQuarterly report · period to Jun 2026
- Jul 20, 20268-KCurrent reportOther events
- May 29, 20268-KCurrent reportShareholder vote
- May 21, 20268-KCurrent reportOther events
- May 21, 20268-KCurrent reportRegulation FD disclosure · Other events
- May 7, 202610-QQuarterly report · period to Mar 2026
- Apr 6, 2026DEF 14AProxy statement
- Mar 30, 20268-KCurrent reportRegulation FD disclosure · Other events
Official filings of Immix Biopharma, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-30 M
- Net income
- $-29 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $105 M
- Total liabilities
- $11 M
- Total equity
- $94 M
As of December-2025
Top 100 institutional investors in Immix Biopharma, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Janus Henderson Group Ltd. | 12,069,267 | — | 14.40% | $126 M | Nov 16, 2026 |
| 2 | Eventide Asset Management, LLC | 5,186,534 | +1,295,515 (+33.30%) | 6.19% | $54 M | Nov 13, 2026 |
| 3 | Saturn V Capital Management LP | 4,661,115 | +2,686 (+0.06%) | 5.56% | $48 M | Nov 16, 2026 |
| 4 | BlackRock, Inc. | 4,539,819 | +1,549,847 (+51.83%) | 5.42% | $47 M | Nov 13, 2026 |
| 5 | State Street Corp | 3,304,389 | +307,454 (+10.26%) | 3.94% | $34 M | Nov 12, 2026 |
| 6 | Vanguard Capital Management LLC | 3,002,000 | +494,878 (+19.74%) | 3.58% | $31 M | Nov 13, 2026 |
| 7 | Opaleye Management Inc. | 2,825,000 | +480,000 (+20.47%) | 3.37% | $29 M | Nov 16, 2026 |
| 8 | Balyasny Asset Management L.P. | 2,642,437 | +2,225,210 (+533.33%) | 3.15% | $27 M | Nov 16, 2026 |
| 9 | Ameriprise Financial Inc | 1,860,770 | +1,341,889 (+258.61%) | 2.22% | $19 M | Nov 16, 2026 |
| 10 | Marshall Wace, LLP | 1,854,215 | +59,307 (+3.30%) | 2.21% | $19 M | Nov 13, 2026 |
| 11 | Franklin Templeton Inc | 1,787,301 | +818,181 (+84.43%) | 2.13% | $19 M | Nov 12, 2026 |
| 12 | Price T Rowe Associates Inc /MD/ | 1,749,800 | +9,881 (+0.57%) | 2.09% | $18 M | Nov 16, 2026 |
| 13 | Wellington Management Group LLP | 1,650,048 | +176,639 (+11.99%) | 1.97% | $17 M | Nov 16, 2026 |
| 14 | Geode Capital Management, LLC | 1,440,734 | +239,637 (+19.95%) | 1.72% | $15 M | Nov 6, 2026 |
| 15 | Alliancebernstein L.P. | 1,322,449 | +1,283,159 (+3265.87%) | 1.58% | $14 M | Nov 16, 2026 |
| 16 | Velan Capital Investment Management LP | 1,085,000 | 0 (0.00%) | 1.29% | $11 M | Nov 16, 2026 |
| 17 | Bleichroeder LP | 1,000,000 | 0 (0.00%) | 1.19% | $10 M | Nov 13, 2026 |
| 18 | Citadel Advisors LLC | 931,361 | +425,204 (+84.01%) | 1.11% | $10 M | Nov 16, 2026 |
| 19 | Millennium Management LLC | 865,940 | -1,200,486 (-58.09%) | 1.03% | $9 M | Nov 16, 2026 |
| 20 | Aberdeen Group plc | 818,674 | New | 0.98% | $9 M | Nov 10, 2026 |
| 21 | Adage Capital Partners GP, L.L.C. | 727,272 | New | 0.87% | $8 M | Nov 16, 2026 |
| 22 | Vanguard Portfolio Management LLC | 607,678 | +323,967 (+114.19%) | 0.72% | $6 M | Nov 13, 2026 |
| 23 | Blue Owl Capital Holdings LP | 602,047 | +164,495 (+37.59%) | 0.72% | $6 M | Nov 13, 2026 |
| 24 | Northern Trust Corp | 521,279 | +103,228 (+24.69%) | 0.62% | $5 M | Nov 16, 2026 |
| 25 | LGT Fund Management Co Ltd. | 461,159 | +44,565 (+10.70%) | 0.55% | $5 M | Nov 13, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Alyeska Investment Group, L.P. | 454,545 | New | 0.54% | $5 M | Nov 16, 2026 |
| 27 | Monashee Investment Management LLC | 450,000 | New | 0.54% | $5 M | Nov 6, 2026 |
| 28 | Vanguard Fiduciary Trust Co | 445,754 | +39,722 (+9.78%) | 0.53% | $5 M | Nov 13, 2026 |
| 29 | Bank Of America Corp /de/ | 429,320 | +16,175 (+3.92%) | 0.51% | $4 M | Nov 16, 2026 |
| 30 | Sphera Funds Management LTD. | 355,800 | +85,800 (+31.78%) | 0.42% | $4 M | Nov 16, 2026 |
| 31 | Institute for Wealth Management, LLC. | 340,002 | +2,450 (+0.73%) | 0.41% | $4 M | Nov 6, 2026 |
| 32 | Picton Mahoney Asset Management | 333,247 | New | 0.40% | $3 M | Nov 9, 2026 |
| 33 | Longaeva Partners L.P. | 318,181 | New | 0.38% | $3 M | Nov 16, 2026 |
| 34 | Qube Research & Technologies Ltd | 309,539 | +167,575 (+118.04%) | 0.37% | $3 M | Nov 13, 2026 |
| 35 | Morgan Stanley | 292,844 | +133,370 (+83.63%) | 0.35% | $3 M | Nov 13, 2026 |
| 36 | Bank of New York Mellon Corp | 288,149 | +52,429 (+22.24%) | 0.34% | $3 M | Nov 5, 2026 |
| 37 | Invesco Ltd. | 279,143 | +256,825 (+1150.75%) | 0.33% | $3 M | Nov 12, 2026 |
| 38 | Seven Grand Managers, LLC | 259,597 | +4,597 (+1.80%) | 0.31% | $3 M | Nov 16, 2026 |
| 39 | Informed Momentum Co LLC | 239,127 | +146,302 (+157.61%) | 0.29% | $2 M | Nov 16, 2026 |
| 40 | KVP Capital Advisors, LP | 230,423 | 0 (0.00%) | 0.27% | $2 M | Nov 16, 2026 |
| 41 | TD Asset Management Inc | 214,090 | 0 (0.00%) | 0.26% | $2 M | Nov 13, 2026 |
| 42 | D. E. Shaw & Co., Inc. | 207,720 | +114,614 (+123.10%) | 0.25% | $2 M | Nov 16, 2026 |
| 43 | Charles Schwab Investment Management Inc | 192,478 | +65,222 (+51.25%) | 0.23% | $2 M | Nov 16, 2026 |
| 44 | UBS Group AG | 186,502 | -1,755,315 (-90.40%) | 0.22% | $2 M | Nov 10, 2026 |
| 45 | Goldman Sachs Group Inc | 130,696 | -43,411 (-24.93%) | 0.16% | $1 M | Nov 16, 2026 |
| 46 | Manufacturers Life Insurance Company, The | 127,514 | -19,340 (-13.17%) | 0.15% | $1 M | Nov 13, 2026 |
| 47 | Nuveen, LLC | 125,122 | +22,143 (+21.50%) | 0.15% | $1 M | Nov 10, 2026 |
| 48 | Rafferty Asset Management, LLC | 89,303 | +30,817 (+52.69%) | 0.11% | $1 M | Nov 13, 2026 |
| 49 | Moore Capital Management, LP | 89,069 | New | 0.11% | $1 M | Nov 16, 2026 |
| 50 | Tocqueville Asset Management L.P. | 87,350 | -1,200 (-1.36%) | 0.10% | $1 M | Nov 13, 2026 |
| 51 | Bridgeway Capital Management, LLC | 80,000 | 0 (0.00%) | 0.10% | $1 M | Nov 16, 2026 |
| 52 | Maven Securities LTD | 76,000 | New | 0.09% | $1 M | Nov 13, 2026 |
| 53 | Squarepoint Ops LLC | 74,242 | +4,180 (+5.97%) | 0.09% | $1 M | Nov 9, 2026 |
| 54 | Aquatic Capital Management LLC | 74,142 | New | 0.09% | $1 M | Nov 16, 2026 |
| 55 | United Capital Financial Advisors, LLC | 70,686 | +4 (+0.01%) | 0.08% | $1 M | Nov 12, 2026 |
| 56 | Susquehanna International Group, LLP | 66,058 | +27,327 (+70.56%) | 0.08% | $1 M | Nov 16, 2026 |
| 57 | Rhumbline Advisers | 65,127 | +14,183 (+27.84%) | 0.08% | $1 M | Nov 10, 2026 |
| 58 | J. Goldman & Co LP | 63,954 | -134,778 (-67.82%) | 0.08% | $1 M | Nov 16, 2026 |
| 59 | Magnetar Financial LLC | 54,524 | +43,570 (+397.75%) | 0.07% | $1 M | Nov 13, 2026 |
| 60 | Gsa Capital Partners LLP | 51,461 | +31,588 (+158.95%) | 0.06% | $1 M | Nov 16, 2026 |
| 61 | Deutsche Bank AG\ | 51,339 | +10,478 (+25.64%) | 0.06% | $1 M | Nov 6, 2026 |
| 62 | Prelude Capital Management, LLC | 48,540 | New | 0.06% | $1 M | Nov 16, 2026 |
| 63 | SEI Investments Co | 45,844 | -21,504 (-31.93%) | 0.05% | $0 M | Nov 10, 2026 |
| 64 | Harvest Investment Services, LLC | 44,737 | New | 0.05% | $0 M | Nov 12, 2026 |
| 65 | Citigroup Inc | 42,864 | -27,790 (-39.33%) | 0.05% | $0 M | Nov 4, 2026 |
| 66 | Vanguard Global Advisers, LLC | 42,222 | +20,127 (+91.09%) | 0.05% | $0 M | Nov 13, 2026 |
| 67 | Virtus Investment Advisers, LLC | 37,554 | -1,167 (-3.01%) | 0.04% | $0 M | Nov 12, 2026 |
| 68 | Jpmorgan Chase & Co | 37,378 | +17,803 (+90.95%) | 0.04% | $0 M | Nov 12, 2026 |
| 69 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 35,457 | +9,828 (+38.35%) | 0.04% | $0 M | Nov 16, 2026 |
| 70 | Private Advisor Group, LLC | 35,429 | +104 (+0.29%) | 0.04% | $0 M | Nov 10, 2026 |
| 71 | Wells Fargo & Company/mn | 35,285 | -78,035 (-68.86%) | 0.04% | $0 M | Nov 16, 2026 |
| 72 | Certuity, LLC | 35,000 | 0 (0.00%) | 0.04% | $0 M | Nov 2, 2026 |
| 73 | Optimize Financial Inc. | 34,626 | New | 0.04% | $0 M | Nov 12, 2026 |
| 74 | MetLife Investment Management, LLC | 34,426 | +9,494 (+38.08%) | 0.04% | $0 M | Nov 16, 2026 |
| 75 | Engineers Gate Manager LP | 34,173 | +16,343 (+91.66%) | 0.04% | $0 M | Nov 16, 2026 |
| 76 | Profund Advisors LLC | 31,431 | +2,126 (+7.25%) | 0.04% | $0 M | Oct 29, 2026 |
| 77 | American Century Companies Inc | 30,580 | New | 0.04% | $0 M | Nov 12, 2026 |
| 78 | C2P Capital Advisory Group, LLC d.b.a. Prosperity Capital Advisors | 30,113 | New | 0.04% | $0 M | Oct 14, 2026 |
| 79 | Bank Of Nova Scotia | 29,400 | New | 0.04% | $0 M | Nov 13, 2026 |
| 80 | Arrowstreet Capital, Limited Partnership | 27,056 | New | 0.03% | $0 M | Nov 13, 2026 |
| 81 | State Of Wisconsin Investment Board | 24,834 | New | 0.03% | $0 M | Nov 16, 2026 |
| 82 | Sowell Financial Services LLC | 24,608 | New | 0.03% | $0 M | Oct 23, 2026 |
| 83 | TritonPoint Partners, LLC | 24,526 | 0 (0.00%) | 0.03% | $0 M | Nov 5, 2026 |
| 84 | Concurrent Investment Advisors, LLC | 24,028 | +28 (+0.12%) | 0.03% | $0 M | Oct 16, 2026 |
| 85 | Barclays PLC | 23,047 | -30,009 (-56.56%) | 0.03% | $0 M | Nov 6, 2026 |
| 86 | Imprint Wealth LLC | 20,938 | -5,295 (-20.18%) | 0.03% | $0 M | Nov 16, 2026 |
| 87 | Wealth Watch Advisors, INC | 20,938 | New | 0.03% | $0 M | Nov 16, 2026 |
| 88 | Quent Capital, LLC | 20,000 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 89 | Boothbay Fund Management, LLC | 19,032 | New | 0.02% | $0 M | Nov 16, 2026 |
| 90 | Voloridge Investment Management, LLC | 18,910 | New | 0.02% | $0 M | Nov 16, 2026 |
| 91 | BNP Paribas Financial Markets | 18,607 | +12,332 (+196.53%) | 0.02% | $0 M | Nov 12, 2026 |
| 92 | Virtu Financial LLC | 16,121 | -7,726 (-32.40%) | 0.02% | $0 M | Nov 17, 2026 |
| 93 | Police & Firemen's Retirement System of New Jersey | 16,065 | +3,950 (+32.60%) | 0.02% | $0 M | Nov 9, 2026 |
| 94 | New York State Common Retirement Fund | 14,300 | -100 (-0.69%) | 0.02% | $0 M | Nov 17, 2026 |
| 95 | Commonwealth Equity Services, LLC | 13,753 | +933 (+7.28%) | 0.02% | $0 M | Nov 2, 2026 |
| 96 | Mathes Company, Inc. | 13,150 | +2,500 (+23.47%) | 0.02% | $0 M | Nov 16, 2026 |
| 97 | Kera Capital Partners, Inc. | 13,000 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 98 | XTX Topco Ltd | 12,378 | -28,117 (-69.43%) | 0.01% | $0 M | Nov 16, 2026 |
| 99 | Voya Investment Management LLC | 11,175 | New | 0.01% | $0 M | Nov 10, 2026 |
| 100 | Royal Bank Of Canada | 10,822 | +9,466 (+698.08%) | 0.01% | $0 M | Nov 16, 2026 |
Mutual funds holding Immix Biopharma, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Eventide Healthcare & Life Sciences FundEventide Asset Management, LLC | 3.89 M | $40 M | 4.6% | 2.2% | +53% | Jun 30, 2026 |
| 🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc. | 2.10 M | $22 M | 2.5% | 0.20% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.78 M | $18 M | 2.1% | <0.01% | +38% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc. | 1.33 M | $14 M | 1.6% | 0.11% | +306% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 1.07 M | $11 M | 1.3% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 681,413 | $7 M | 0.81% | <0.01% | +49% | Jun 30, 2026 |
| 🇺🇸 Columbia Small Cap Value Discovery FundColumbia Management Investment Advisers, LLC | 483,630 | $4 M | 0.58% | 0.16% | new | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 370,703 | $4 M | 0.44% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 449,259 | $4 M | 0.54% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc. | 357,034 | $3 M | 0.43% | 0.26% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 298,586 | $3 M | 0.36% | <0.01% | +158% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 138,125 | $1 M | 0.16% | 0.09% | +59% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 109,438 | $1 M | 0.13% | <0.01% | +188% | May 31, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc. | 82,613 | $1 M | 0.10% | 0.11% | +313% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 99,794 | $1 M | 0.12% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 88,336 | $1 M | 0.11% | <0.01% | +190% | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 76,786 | $1 M | 0.09% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC | 71,495 | $1 M | 0.09% | 0.12% | new | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 44,723 | $0 M | 0.05% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 54,609 | $0 M | 0.07% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 38,484 | $0 M | 0.05% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 47,380 | $0 M | 0.06% | <0.01% | +73% | Jul 31, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 33,534 | $0 M | 0.04% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Columbia Variable Portfolio - Small Company Growth FundColumbia Management Investment Advisers, LLC | 30,390 | $0 M | 0.04% | 0.12% | new | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 29,800 | $0 M | 0.04% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 36,034 | $0 M | 0.04% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC | 27,992 | $0 M | 0.03% | 0.11% | +289% | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 22,835 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 22,585 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 21,124 | $0 M | 0.03% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 22,933 | $0 M | 0.03% | <0.01% | +36% | May 31, 2026 |
| 🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC | 19,704 | $0 M | 0.02% | 0.12% | +294% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 16,780 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 16,780 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 19,540 | $0 M | 0.02% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 14,902 | $0 M | 0.02% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 14,396 | $0 M | 0.02% | 0.04% | −4.1% | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 14,300 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 14,131 | $0 M | 0.02% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 11,790 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Multi-Manager U.S. Small Cap Equity FundGoldman Sachs Asset Management, L.P. | 10,622 | $0 M | 0.01% | 0.03% | — | Apr 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 9,203 | $0 M | 0.01% | 0.04% | +49% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 9,166 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 8,523 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 8,692 | $0 M | 0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 6,452 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 6,235 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 6,193 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 7,122 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 5,559 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 5,061 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 6,245 | $0 M | <0.01% | <0.01% | +37% | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 4,810 | $0 M | <0.01% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 3,756 | $0 M | <0.01% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 3,728 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 4,611 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 3,284 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 3,633 | $0 M | <0.01% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 2,863 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 3,543 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 1,848 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 1,435 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 1,037 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 872 | $0 M | <0.01% | <0.01% | +39% | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 231 | $0 M | <0.01% | <0.01% | +6.0% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 65 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Immix Biopharma, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Jason HsuDirector | Grant or award | +6,250 | — | — | 899,250 | Form 4 |
| filed | Carey NgDirector | Grant or award | +6,250 | — | — | 26,250 | Form 4 |
| filed | Jane BuchanDirector | Grant or award | +6,250 | — | — | 28,705 | Form 4 |
| filed | Helen C. AdamsDirector | Grant or award | +6,250 | — | — | 181,004 | Form 4 |
| filed | Yekaterina ChudnovskyDirector | Grant or award | +6,250 | — | — | 6,250 | Form 4 |
| filed | Magda MarquetDirector | Grant or award | +6,250 | — | — | 52,342 | Form 4 |
| filed | Nancy T. ChangDirector | Grant or award | +6,250 | — | — | 428,190 | Form 4 |
| filed | Ilya M. RachmanCEO and Chairman, Director | Buy | +746 | $6.670 | $5 K | 1.14 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Immix Biopharma, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2022 | Q4 2022 | $0M |
| Q3 2022 | Q3 2022 | $0M |
Fails to deliver
- : 391 shares at $8.05
- : 300 shares at $8.15
- : 6,423 shares at $8.35
- : 25 shares at $7.98
- : 1,270 shares at $8.68
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Immix Biopharma, Inc. scorecard#
Passes 1 of the 12 checks that could be worked out. Fiscal year 2025; market cap of Oct 28, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median7.2×Price to book 7.2× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-3.7%Free cash flow is -3.7% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.89 vs -0.76Diluted EPS -0.89 in fiscal 2025 against -0.76 the year before (report's currency).
- ✗Net income higher than five years earlier-$29 M-$29 M in fiscal 2025 against -$1 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$29 MNet income -$29 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-55.0%-55.0% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities10.0×Current ratio 10.01 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year16.6%Diluted shares up 16.6% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Immix Biopharma, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Research and development | 16+44.0%— | 11+29.3%— | 8.7+108%— | 4.2+3216%— | 0.1−49.0%— | 0.2—— | |
| General and administrative | 14+20.3%— | 11+53.7%— | 7.4+84.1%— | 4.0+228%— | 1.2+496%— | 0.2—— | |
| Operating expenses | 30+32.1%— | 23+40.5%— | 16+96.4%— | 8.2+508%— | 1.4+198%— | 0.5—— | |
| Operating income | −30—— | −23—— | −16—— | −8.2—— | −1.4—— | −0.5—— | |
| Interest and finance income | 0.6−45.4%— | 1.0+77.9%— | 0.6—— | — | — | — | |
| Interest expense and finance costs | — | — | — | 0.0−99.7%— | 0.2+76.4%— | 0.1—— | |
| Other non-operating income (expense) | 0.6−45.4%— | 1.0+77.9%— | 0.6—— | −0.0—— | −23—— | −0.7—— | |
| Income before tax | −29—— | −22—— | −16—— | −8.2—— | −24—— | −1.1—— | |
| Income tax | 0.0−8.1%— | 0.0+55.4%— | 0.0+157%— | 0.0+70.8%— | 0.0−65.7%— | 0.0—— | |
| Net income including minority interests | −29—— | −22—— | −16—— | −8.2—— | −24—— | — | |
| Minority interests' share of net income | — | −0.1—— | −0.2—— | — | — | — | |
| Net income attributable to shareholders | −29—— | −22—— | −15—— | −8.2—— | −24—— | −1.1—— | |
| Earnings per share, basic | -0.89—— | -0.76—— | -0.89—— | -0.59—— | -6.64—— | -0.34—— | |
| Earnings per share, diluted | -0.89—— | -0.76—— | -0.89—— | -0.59—— | -6.64—— | -0.34—— | |
| Shares, weighted average (basic) | 33+16.5%— | 28+63.1%— | 17+24.9%— | 14+278%— | 3.7—— | — | |
| Shares, weighted average (diluted) | 33+16.5%— | 28+63.1%— | 17+24.9%— | 14+278%— | 3.7+8.8%— | 3.4—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 94+431%89.6% | 18+1.0%77.1% | 18+30.3%87.9% | 13−23.8%90.1% | 18+4412%97.0% | 0.4—72.5% | |
| Short-term investments | 6.5—6.2% | — | — | — | — | — | |
| Other current assets | 0.2+367%0.1% | 0.0−27.6%0.1% | 0.0−42.9%0.2% | 0.1r1.2−84.9%0.5% | 0.5+3664%2.8% | 0.0—2.5% | |
| Current assets | 101+401%96.6% | 20+2.1%88.0% | 20+32.8%99.3% | 15−18.1%99.9% | 18+3317%100.0% | 0.5—98.6% | |
| Property, plant and equipment | 2.5+44.9%2.4% | 1.7+3368%7.6% | 0.1+1310%0.3% | 0.0−37.5%0.0% | 0.0−22.6%0.0% | 0.0—1.4% | |
| Right-of-use (leased) assets | 1.0−2.3%0.9% | 1.0—4.3% | — | — | — | — | |
| Total assets | 105+357%100% | 23+15.2%100% | 20+33.7%100% | 15−18.1%100% | 18+3271%100% | 0.5—100% | |
| Accounts payable | 5.4+1.0%5.2% | 5.4+276%23.5% | 1.4+902%7.2% | 0.1r1.3+0.1%1.0% | 0.1−43.4%0.8% | 0.3—46.8% | |
| Current liabilities | 10+16.4%9.6% | 8.7+133%37.9% | 3.7+192%18.7% | 1.3+530%8.5% | 0.2−96.2%1.1% | 5.3—977% | |
| Lease liabilities (non-current) | 0.9−7.5%0.9% | 1.0—4.4% | — | — | — | — | |
| Total liabilities | 11+13.9%10.5% | 9.7+161%42.3% | 3.7+113%18.7% | 1.7+765%11.7% | 0.2−96.2%1.1% | 5.3—977% | |
| Retained earnings | −104—−99.6% | −75—−327% | −53—−268% | −38—−255% | −30—−164% | −5.4—−995% | |
| Shareholders' equity | 94+608%89.5% | 13−19.2%57.7% | 16+24.7%82.3% | 13−26.8%88.3% | 18—98.9% | −4.7—−877% | |
| Minority interests | — | — | −0.2—−1.0% | — | — | — | |
| Total equity | 94+608%89.5% | 13−18.2%57.7% | 16+23.1%81.3% | 13−26.8%88.3% | 18—98.9% | −4.7—−877% | |
| Total liabilities and equity | 105+357%100% | 23+15.2%100% | 20+33.7%100% | 15−18.1%100% | 18+3271%100% | 0.5—100% | |
| Shares outstanding | 53+92.3%— | 28+38.2%— | 20+43.4%— | 14+5.0%— | 13+292%— | 3.4—— | |
| Cash-flow statement | |||||||
| Share-based compensation | 2.4−19.2%— | 3.0+17.7%— | 2.6+311%— | 0.6r0.5+185%— | 0.2—— | — | |
| Cash from operating activities | −24—— | −15—— | −11—— | −7.4—— | −1.6—— | −0.4—— | |
| Capital expenditure | −0.7—— | −1.2—— | −0.1—— | — | −0.0—— | — | |
| Cash from investing activities | −7.2—— | −1.2—— | −0.1—— | — | −0.0—— | — | |
| Shares issued | 107+573%— | 16+2.7%— | 16+433%— | 2.9−84.4%— | 19—— | — | |
| Shares bought back | — | — | — | −0.1—— | — | — | |
| Cash from financing activities | 107+573%— | 16+3.1%— | 15+378%— | 3.2−82.9%— | 19—— | — | |
| Exchange-rate effect on cash | 0.0—— | −0.0−111%— | 0.0—— | −0.0—— | −0.0−109%— | 0.1—— | |
| Change in cash | 76+44187%— | 0.2−95.8%— | 4.1—— | −4.2−124%— | 17—— | −0.3—— | |
| Report | 10-K/A | 10-K/A | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 23+89.7%— | 5.5+20.9%— | 5.3+34.3%— | 6.0+203%— | 5.7*+317%— | 4.6+3.1%— | 4.0+78.6%— | 2.0−39.2%— | 1.4*−55.7%— | 4.4—— | 2.2—— | 3.2—— | 3.1*—— | |
| General and administrative | 28+127%— | 10+238%— | 7.1+159%— | 4.8+78.1%— | 5.2*+43.0%— | 3.1+4.4%— | 2.7+10.8%— | 2.7+15.6%— | 3.6*+58.8%— | 2.9—— | 2.5—— | 2.3—— | 2.3*—— | |
| Operating expenses | 50+108%— | 16+108%— | 12+85.4%— | 11+131%— | 11*+118%— | 7.7+3.6%— | 6.7+42.9%— | 4.7−16.2%— | 5.0*−7.2%— | 7.4—— | 4.7—— | 5.6—— | 5.4*—— | |
| Operating income | −50—— | −16—— | −12—— | −11—— | −11*—— | −7.7—— | −6.7—— | −4.7—— | −5.0*—— | −7.4—— | −4.7—— | −5.6—— | −5.4*—— | |
| Interest and finance income | 3.9+637%— | 2.0+2288%— | 0.9+778%— | 0.7+377%— | 0.2*+16.6%— | 0.1−67.1%— | 0.1−66.1%— | 0.2−43.9%— | 0.2*−18.7%— | 0.3—— | 0.3—— | 0.3—— | 0.2*—— | |
| Other non-operating income (expense) | 3.9+637%— | 2.0+2288%— | 0.9+778%— | 0.7+377%— | 0.2*+16.6%— | 0.1−67.1%— | 0.1−66.1%— | 0.2−43.9%— | 0.2*−18.7%— | 0.3—— | 0.3—— | 0.3—— | 0.2*—— | |
| Income before tax | −46—— | −14—— | −12—— | −10—— | −11*—— | −7.6—— | −6.6—— | −4.5—— | −4.8*—— | −7.1—— | −4.4—— | −5.3—— | −5.1*—— | |
| Income tax | — | 0*−100%— | 0.0+60.7%— | — | 0.0*+4.5%— | 0.0−30.7%— | 0.0−13.2%— | 0.0+11.1%— | 0.0*+33.3%— | 0.0—— | 0.0—— | 0.0—— | 0.0*—— | |
| Net income including minority interests | — | — | — | −10—— | −11*—— | −7.6—— | −6.6—— | −4.5—— | −4.8*—— | −7.1—— | −4.4—— | −5.3—— | −5.2*—— | |
| Minority interests' share of net income | — | — | — | — | — | — | — | — | 0*—— | 0*—— | −0.0—— | −0.1—— | −0.1*—— | |
| Net income attributable to shareholders | −46—— | −14—— | −12—— | −10—— | −11*—— | −7.6—— | −6.6—— | −4.5—— | −4.8*—— | −7.1—— | −4.4—— | −5.3—— | −5.1*—— | |
| Earnings per share, basic | — | -0.19—— | -0.18—— | -0.18—— | — | -0.24—— | -0.22—— | -0.15—— | — | -0.24—— | -0.15—— | -0.22—— | — | |
| Earnings per share, diluted | — | -0.19—— | -0.18—— | -0.18—— | — | -0.24—— | -0.22—— | -0.15—— | — | -0.24—— | -0.15—— | -0.22—— | — | |
| Shares, weighted average (basic) | 74+132%— | 74+132%— | 64+113%— | 55+86.4%— | — | 32+8.5%— | 30+4.2%— | 30+26.7%— | — | 29—— | 29—— | 23—— | — | |
| Shares, weighted average (diluted) | 74+132%— | 74+132%— | 64+113%— | 55+86.4%— | — | 32+8.5%— | 30+4.2%— | 30+26.7%— | — | 29—— | 29—— | 23—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 320—92.6% | 320+1909%92.6% | 225+1838%94.3% | 79+398%82.7% | 94+431%89.6% | 16−19.0%79.4% | 12−51.5%74.4% | 16−45.7%80.0% | 18+1.0%77.1% | 20—78.3% | 24—83.1% | 29—85.4% | 18—87.9% | |
| Short-term investments | 16—4.6% | 16—4.6% | 6.6—2.8% | 11—11.8% | 6.5—6.2% | — | — | — | — | — | — | — | — | |
| Other current assets | 0.1—0.0% | 0.1−13.2%0.0% | 0.3+103%0.1% | 0.3+99.4%0.4% | 0.2+367%0.1% | 0.1+264%0.7% | 0.1+30.2%0.9% | 0.2−3.9%0.8% | 0.0−27.6%0.1% | 0.0—0.1% | 0.1—0.4% | 0.2—0.5% | 0.0—0.2% | |
| Current assets | 338—97.7% | 338+1939%97.7% | 234+1797%97.8% | 92+450%96.3% | 101+401%96.6% | 17−27.1%82.6% | 12−54.9%78.8% | 17−49.0%84.4% | 20+2.1%88.0% | 23—90.5% | 27—94.8% | 33—95.8% | 20—99.3% | |
| Property, plant and equipment | 2.4—0.7% | 2.4+2.2%0.7% | 2.4+5.7%1.0% | 2.4+14.3%2.5% | 2.5+44.9%2.4% | 2.4+74.0%11.7% | 2.2+391%14.3% | 2.1+489%10.7% | 1.7+3368%7.6% | 1.4—5.4% | 0.5—1.6% | 0.4—1.1% | 0.1—0.3% | |
| Right-of-use (leased) assets | 0.9—0.3% | 0.9−13.8%0.3% | 0.9−6.3%0.4% | 0.9−4.2%1.0% | 1.0−2.3%0.9% | 1.0−0.5%5.0% | 0.9−8.1%6.1% | 1.0−7.9%4.9% | 1.0—4.3% | 1.0—4.0% | 1.0—3.6% | 1.1—3.1% | — | |
| Long-term investments | 4.6—1.3% | 4.6—1.3% | 2.1—0.9% | — | — | — | — | — | — | — | — | — | — | |
| Total assets | 346—100% | 346+1623%100% | 239+1429%100% | 96+382%100% | 105+357%100% | 20−20.1%100% | 16−45.8%100% | 20−42.1%100% | 23+15.2%100% | 25—100% | 29—100% | 34—100% | 20—100% | |
| Accounts payable | 5.6—1.6% | 5.6−20.6%1.6% | 5.3−20.2%2.2% | 4.7−17.6%4.9% | 5.4+1.0%5.2% | 7.1+114%35.1% | 6.6+182%42.3% | 5.7+63.5%28.9% | 5.4+276%23.5% | 3.3—13.1% | 2.3—8.1% | 3.5—10.2% | 1.4—7.2% | |
| Current liabilities | 10—2.9% | 10−7.6%2.9% | 9.3−7.1%3.9% | 11+13.2%11.0% | 10+16.4%9.6% | 11+65.3%54.0% | 10+157%64.0% | 9.3+64.5%46.8% | 8.7+133%37.9% | 6.6—26.1% | 3.9—13.5% | 5.7—16.5% | 3.7—18.7% | |
| Lease liabilities (non-current) | 0.9—0.3% | 0.9−10.0%0.3% | 0.9−8.4%0.4% | 0.9−7.9%1.0% | 0.9−7.5%0.9% | 1.0−6.0%4.8% | 1.0−6.8%6.2% | 1.0−6.4%5.0% | 1.0—4.4% | 1.0—4.1% | 1.0—3.6% | 1.1—3.1% | — | |
| Total liabilities | 11—3.1% | 11−7.8%3.1% | 10−7.2%4.3% | 11+11.2%12.0% | 11+13.9%10.5% | 12+55.7%58.8% | 11+122%70.2% | 10+53.3%51.8% | 9.7+161%42.3% | 7.6—30.2% | 4.9—17.1% | 6.7—19.6% | 3.7—18.7% | |
| Retained earnings | −140—−40.5% | −140—−40.5% | −126—−52.7% | −115—−120% | −104—−99.6% | −94—−467% | −86—−551% | −80—−400% | −75—−327% | −70—−279% | −63—−219% | −59—−171% | −53—−268% | |
| Shareholders' equity | 335—96.9% | 335+3954%96.9% | 229+4820%95.7% | 84+779%88.0% | 94+608%89.5% | 8.3−52.9%41.2% | 4.7−80.5%29.8% | 9.6−65.6%48.2% | 13−19.2%57.7% | 18—69.8% | 24—82.9% | 28—81.3% | 16—82.3% | |
| Minority interests | — | — | — | — | — | — | — | — | — | — | — | −0.3—−0.8% | −0.2—−1.0% | |
| Total equity | — | — | 229+4820%95.7% | 84+779%88.0% | 94+608%89.5% | 8.3−52.9%41.2% | 4.7−80.5%29.8% | 9.6−65.3%48.2% | 13−18.2%57.7% | 18—69.8% | 24—82.9% | 28—80.4% | 16—81.3% | |
| Total liabilities and equity | 346—100% | 346+1623%100% | 239+1429%100% | 96+382%100% | 105+357%100% | 20−20.1%100% | 16−45.8%100% | 20−42.1%100% | 23+15.2%100% | 25—100% | 29—100% | 34—100% | 20—100% | |
| Shares outstanding | 84—— | 84+154%— | 72+152%— | 53+90.3%— | 53+92.3%— | 33+20.2%— | 28+3.6%— | 28+5.5%— | 28+38.2%— | 27—— | 27—— | 26—— | 20—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 2.1−17.6%— | 0−100%— | 1.0*+83.8%— | 0.6−33.7%— | 0.6*−19.1%— | 0.5*−35.9%— | 0.5*−16.6%— | 0.9−7.9%— | 0.7*−32.8%— | 0.7*—— | 0.6*—— | 0.9—— | 1.1*—— | |
| Cash from operating activities | −45—— | −12*—— | −12*—— | −9.8—— | −11*—— | −5.9*—— | −5.3*—— | −1.7—— | −1.5*—— | −4.0*—— | −5.3*—— | −3.8—— | −2.7*—— | |
| Capital expenditure | −0.3—— | −0.1*—— | −0.0*—— | −0.0—— | −0.2*—— | −0.4*—— | −0.1*—— | −0.1—— | −0.5*—— | −0.3*—— | −0.1*—— | −0.3—— | −0.0*—— | |
| Cash from investing activities | −21—— | −12*—— | 2.7*—— | −4.8—— | −6.6*—— | −0.4*—— | −0.1*—— | −0.1—— | −0.5*—— | −0.3*—— | −0.1*—— | −0.3—— | −0.0*—— | |
| Shares issued | — | 118*+991%— | — | — | 96*—— | 11*—— | — | — | 0*−100%— | 0*—— | 0*—— | 16—— | 0.6*—— | |
| Cash from financing activities | 370—— | 119*+1023%— | 155*—— | −0.0—— | 96*—— | 11*—— | — | — | 0*−100%— | 0*—— | 0*—— | 16—— | 0.6*—— | |
| Exchange-rate effect on cash | −0.0—— | −0.0*—— | 0.0*−44.1%— | −0.0—— | −0.0*—— | −0.0*−190%— | 0.0*+395%— | −0.0—— | −0.0*−180%— | 0.0*—— | 0.0*—— | −0.0—— | 0.0*—— | |
| Change in cash | 304—— | 95*+2100%— | 146*—— | −15—— | 78*—— | 4.3*—— | −4.3*—— | −1.8−115%— | −2.0*—— | −4.3*—— | −5.3*—— | 12—— | −2.1*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K/A | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Immix Biopharma, Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 4 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office3 subsidiaries | — |
| 🇦🇺 Australia | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Events at Immix Biopharma, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Auditor changedFiling
Auditor changed 1 · Directors and officers 2 · Material agreement 5 · Unregistered share sale 2 · Shareholder vote 3 · Results announced 1
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Directors and officersMaterial agreementUnregistered share sale | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Auditor changed | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Unregistered share sale | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Lobbying by Immix Biopharma, Inc.#
$480 K spent on lobbying the US Congress and federal agencies in 2026, most often on health issues and medical/disease research/clinical labs.
- Health Issues7 reports
- Medical/Disease Research/Clinical Labs2 reports
Lobbying firms hired in 2026
CONTINENTAL STRATEGY, LLC $260 K · Tarplin, Downs & Young, LLC $100 K · AxAdvocacy Government Relations $80 K · YC Consulting, LLC $20 K · FIRST PRINCIPLES STRATEGIES, LLC $20 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $480 K | — | 10 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Immix Biopharma, Inc.”, “Immix Biopharma Inc” and “Immix Biopharma Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
Discuss Immix Biopharma, Inc.#
2 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 12 November 2026automatic update · Nov 12, 2026
Immix Biopharma, Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $14 million.
- Mutual funds: 65 funds hold $142 millionautomatic update · Jul 31, 2026
65 mutual funds in 1 country hold shares of Immix Biopharma, Inc. worth $142 million, about 16.9% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 60 funds added shares and 1 sold; on balance they bought $88 million. Share splits are not counted as trading.
How Immix Biopharma, Inc. compares in Biotechnology
- Market cap$675 M · higher than 62% of 726
- Price / book7.2× · lower than 22% of 534
- FCF yield-3.7% · higher than 75% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Immix Biopharma, Inc.🇺🇸 | $675 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Candel Therapeutics, Inc.$679 M
- Aura Biosciences, Inc.$666 M
- Lexicon Pharmaceuticals, Inc.$659 M
- Olema Pharmaceuticals, Inc.$694 M
- CorMedix Inc.$652 M
- AgomAb Therapeutics NV$651 M
Sources and freshness
- Market cap:
- Oct 28, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of March 20, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Immix Biopharma, Inc.? Verify and update this profile — free
Show Immix Biopharma, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.